Humacyte, Inc. — Form SCHEDULE 13D/A
Filed July 13, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
▼ Likely negative
significance 28/100
What the filing says
Fresenius Medical Care Holdings, Inc. adopted a Rule 10b5-1 trading plan on July 10, 2026, appointing Citigroup Global Markets Inc. (CGMI) as its agent to systematically sell Humacyte shares. The plan specifies a $0.02 per share commission to CGMI but does not disclose the exact number of Humacyte shares held by Fresenius or the total dollar value of the planned sale in the document text provided (details are referenced as on 'Schedule A attached hereto,' which is not included). Sales will commence 30 days after adoption (unless later specified), subject to Rule 144 compliance.
Why this rating
Insider/major holder selling plan announced; no specific share count or dollar amount disclosed in filing text. Material only if Fresenius holds substantial stake relative to ~$280M market cap; plan itself is routine for such transactions.
See more from July 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.